Key points are not available for this paper at this time.
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP14)1 May 2024MP14-09 DEVELOPMENT OF A PREDICTION MODEL OF SURVIVAL AMONGST PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) USING BIG DATA: INTERIM RESULTS FROM THE EUROPEAN NETWORK OF EXCELLENCE FOR BIG DATA IN PROSTATE CANCER (PIONEER) Rossella Nicoletti, Juan Gomez Rivas, Laura Ibáñez, Carl Steinbeisserc, Bertrand de Meulder, Asieh Golozar, Susan Evans Axelsson, Robert Snijder, Anders Bjartell, Philip Cornford, Mieke Van Hemelrijck, Katharina Beyer, Peter-Paul Willemse, Teemu Murtola, Monique J. Robool, Jesus Moreno Sierra, Riccardo Campi, Mauro Gacci, Nicolas Mottet, Axel Merseburger, James Ndow, and Rossella Nicoletti Rossella NicolettiRossella Nicoletti , Juan Gomez RivasJuan Gomez Rivas , Laura IbáñezLaura Ibáñez , Carl SteinbeissercCarl Steinbeisserc , Bertrand de MeulderBertrand de Meulder , Asieh GolozarAsieh Golozar , Susan Evans AxelssonSusan Evans Axelsson , Robert SnijderRobert Snijder , Anders BjartellAnders Bjartell , Philip CornfordPhilip Cornford , Mieke Van HemelrijckMieke Van Hemelrijck , Katharina BeyerKatharina Beyer , Peter-Paul WillemsePeter-Paul Willemse , Teemu MurtolaTeemu Murtola , Monique J. RoboolMonique J. Robool , Jesus Moreno SierraJesus Moreno Sierra , Riccardo CampiRiccardo Campi , Mauro GacciMauro Gacci , Nicolas MottetNicolas Mottet , Axel MerseburgerAxel Merseburger , James NdowJames Ndow , and Rossella NicolettiRossella Nicoletti View All Author Informationhttps://doi.org/10.1097/01.JU.0001009428.69695.82.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Androgen deprivation therapy (ADT) was the standard of care (SOC) for patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) for decades; recently, emerging therapies (ARTA, Taxane-based Chemotherapy and their combinations) plus ADT have proven to be more effective than ADT alone. However, metastatic disease is still a clinical state that remains poorly understood. Recently, Real-world Data were be claimed to have potential for generating real-world evidence aiming to answer questions that may not be addressed otherwise. We aim to develop and present preliminary results of a predictive model for Survival amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission using RWD under the PIONEER project. METHODS: Data of patients with mHSPC across a distributed network of observational databases were collected. Male patients without prior ADT with mHSPC were enrolled in Cohort 1, while Cohort 2 was defined as the start of ADT as a surrogate definition of mHSPC disease. Patients were further stratified in metachronous (cohort 1.1 and 2.1) and synchronous (cohort 1.2 and 2.2) disease. RESULTS: Overall, 94,261 mHSPC patients were included in cohort 1 and 77,123 patients in cohort 2. The variables increasing Death Odds were: Age >90, Non-ADC variants, M1c disease and Liver metastasis; The variables decreasing Death Odds were: Age <80, adenocarcinoma of the prostate, M1a-M1b disease, Grade Group 3 or lower and cT1 Disease. The 60% of deaths occur in the first two years after date of diagnosis. We can only predict Survival in the first year with an accuracy of 75%: This is due to many factors, the major factor is that mHSPC patients are non-uniform, and there is a need to better risk stratification of these patients. Other factors could be loss of follow-up and missing data. CONCLUSIONS: This is the largest study in Europe with RWD in the mHSPC setting. Landscape of prostate cancer treatment is constantly evolving, so it is important to understand the behavior of the disease in real-world setting: Our prediction models shows promising results, however a large validation cohort is needed to confirm the reliability of our findings. Source of Funding: PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union's Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI sup- ports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e223 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Rossella Nicoletti More articles by this author Juan Gomez Rivas More articles by this author Laura Ibáñez More articles by this author Carl Steinbeisserc More articles by this author Bertrand de Meulder More articles by this author Asieh Golozar More articles by this author Susan Evans Axelsson More articles by this author Robert Snijder More articles by this author Anders Bjartell More articles by this author Philip Cornford More articles by this author Mieke Van Hemelrijck More articles by this author Katharina Beyer More articles by this author Peter-Paul Willemse More articles by this author Teemu Murtola More articles by this author Monique J. Robool More articles by this author Jesus Moreno Sierra More articles by this author Riccardo Campi More articles by this author Mauro Gacci More articles by this author Nicolas Mottet More articles by this author Axel Merseburger More articles by this author James Ndow More articles by this author Rossella Nicoletti More articles by this author Expand All Advertisement PDF downloadLoading ...
Nicoletti et al. (Mon,) studied this question.